Impax Laboratories, LLC
🏢 View company profile →27Patents
24Active
27Granted
61Portfolio score
Filing activity: Aug 9, 2000 → Dec 30, 2024 · 2 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6333332A | Stabilized pharmaceutical compositions containing bupropion hydrochloride | Human Necessities | 148 | Expired |
| US7094427B2 | Combination immediate release controlled release levodopa/carbidopa dosage forms | Human Necessities | 50 | Expired |
| US8377474B2 | Controlled release formulations of levodopa and uses thereof | Chemistry; Metallurgy | 39 | Active |
| US10098845B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 23 | Active |
| US10688058B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 23 | Active |
| US10292935B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 22 | Active |
| US10987313B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 21 | Active |
| US10973769B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 20 | Active |
| US8007827B2 | Pharmaceutical dosage forms having immediate release and/or controlled release properties | Human Necessities | 17 | Active |
| US11357733B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 13 | Active |
| US11666538B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 11 | Active |
| US11622941B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 11 | Active |
| US8557283B2 | Controlled release formulations of levodopa and uses thereof | Chemistry; Metallurgy | 7 | Active |
| US6531158B1 | Drug delivery system for enhanced bioavailability of hydrophobic active ingredients | Human Necessities | 6 | Expired |
| US9089608B2 | Controlled release formulations of levodopa and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US9089607B2 | Controlled release formulations of levodopa and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US8454998B2 | Controlled release formulations of levodopa and uses thereof | Chemistry; Metallurgy | 3 | Active |
| US9463246B2 | Controlled release formulations of levodopa and uses thereof | Chemistry; Metallurgy | 3 | Active |
| US12178919B2 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US12064521B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US12403099B2 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US9901640B2 | Controlled release formulations of levodopa and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12274793B2 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US9533046B2 | Controlled release formulations of levodopa and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12303605B2 | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.